Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3,...

Keywords

DocetaxelNintedanibMedicinePlaceboLung cancerOncologyInternal medicineDouble blindClinical trialChemotherapyLungAlternative medicinePathologyIdiopathic pulmonary fibrosis

Affiliated Institutions

Related Publications

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst , Paul Baas , Dong‐Wan Kim +16 more

2015 The Lancet 6378 citations

The National Lung Screening Trial: Overview and Study Design

Constantine A. Gatsonis , Denise R. Aberle , Christine D. Berg +97 more

The National Lung Screening Trial (NLST) is a randomized multicenter study comparing low-dose helical computed tomography (CT) with chest radiography in the screening of older c...

2010 Radiology 1227 citations

Publication Info

Year: 2014
Type: article
Volume: 15
Issue: 2
Pages: 143-155
Citations: 923
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

923

OpenAlex

Cite This

APA Style

                            
                                
                                    Martin Reck, 
                                
                                    R. Kaiser, 
                                
                                    Anders Mellemgaard
                                
                                et al.
                            
                            (2014). 
                            Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. 
                            The Lancet Oncology
                            , 15
                            (2)
                            , 143-155.
                            https://doi.org/10.1016/s1470-2045(13)70586-2
                        

Identifiers

DOI: 10.1016/s1470-2045(13)70586-2